Show simple item record

dc.contributor.authorFortuin-de Smidt, M
dc.contributor.authorde Waal, R
dc.contributor.authorCohen, K
dc.contributor.authorTechnau, KG
dc.contributor.authorStinson, K
dc.contributor.authorMaartens, G
dc.contributor.authorBoulle, A
dc.contributor.authorIgumbor, EU
dc.contributor.authorDavies, MA
dc.date.accessioned2017-02-28T21:21:07Z
dc.date.available2017-02-28T21:21:07Z
dc.date.issued2017-02-13
dc.date.submitted2017-02-27
dc.identifier.citationFirst-Line Antiretroviral Drug Discontinuations in Children. 2017, 12 (2):e0169762 PLoS ONEen
dc.identifier.issn1932-6203
dc.identifier.pmid28192529
dc.identifier.doi10.1371/journal.pone.0169762
dc.identifier.urihttp://hdl.handle.net/10144/618811
dc.description.abstractThere are a limited number of paediatric antiretroviral drug options. Characterising the long term safety and durability of different antiretrovirals in children is important to optimise management of HIV infected children and to determine the estimated need for alternative drugs in paediatric regimens. We describe first-line antiretroviral therapy (ART) durability and reasons for discontinuations in children at two South African ART programmes, where lopinavir/ritonavir has been recommended for children <3 years old since 2004, and abacavir replaced stavudine as the preferred nucleoside reverse transcriptase inhibitor in 2010.
dc.language.isoenen
dc.publisherPublic Library of Scienceen
dc.rightsPublished by Public Library of Science, [url]http://www.plosone.org/[/url] Archived on this site by Open Access permissionen
dc.titleFirst-Line Antiretroviral Drug Discontinuations in Childrenen
dc.identifier.journalPloS Oneen
refterms.dateFOA2019-03-04T13:12:22Z
html.description.abstractThere are a limited number of paediatric antiretroviral drug options. Characterising the long term safety and durability of different antiretrovirals in children is important to optimise management of HIV infected children and to determine the estimated need for alternative drugs in paediatric regimens. We describe first-line antiretroviral therapy (ART) durability and reasons for discontinuations in children at two South African ART programmes, where lopinavir/ritonavir has been recommended for children <3 years old since 2004, and abacavir replaced stavudine as the preferred nucleoside reverse transcriptase inhibitor in 2010.


Files in this item

Thumbnail
Name:
Fortuin-de-Smidt M et al - 2017 ...
Size:
771.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record